Related Experiment Videos
Depressive symptoms in a treated multiple sclerosis cohort.
Scott B Patten1, Shanika Fridhandler, Cynthia A Beck
1Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada. patten@ucalgary.ca
Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 11, 2003
Summary
Multiple sclerosis (MS) treatments, including interferon beta and glatiramer acetate, do not appear to increase the risk of depression in real-world settings. This observational study found no significant differences in depression rates between treatment groups.
Area of Science:
- Neurology
- Clinical Research
- Pharmacovigilance
Background:
- Clinical trials for multiple sclerosis (MS) treatments like interferon beta have not confirmed an increased depression risk.
- However, trial samples are highly selected, limiting generalizability to real-world patient populations.
Purpose of the Study:
- To investigate the association between disease-modifying treatments for MS and depressive symptoms in a real-world setting.
- To determine if treatments such as interferon beta or glatiramer acetate are linked to depression.
Main Methods:
- Utilized longitudinal clinical data from patients in southern Alberta seeking MS treatment reimbursement.
- Included depression ratings from the Center for Epidemiological Studies Depression Rating Scale (CES-D).
- Analyzed data to compare depression prevalence and incidence across different treatment groups.
Main Results:
- 163 subjects had baseline depression ratings; treatment groups (interferon beta vs. glatiramer acetate) were comparable.
- No significant differences in the prevalence or incidence of depression were observed during follow-up.
- Center for Epidemiological Studies Depression Rating Scale (CES-D) scores did not differ between treatment groups.
Conclusions:
- The study confirms that interferon beta and glatiramer acetate are not substantially associated with an increased occurrence of depression.
- Findings align with previous intervention studies, suggesting these MS therapies are safe regarding mood.
- Real-world data supports the lack of a significant link between these MS treatments and depression.